Kronos Bio, Inc.

NasdaqGS KRON

Kronos Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 94.64 M

Kronos Bio, Inc. Net Cash Used For Investing Activities is USD 94.64 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 42.21% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Kronos Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 66.54 M, a 363.97% change year over year.
Kronos Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -25.21 M, a 81.16% change year over year.
Kronos Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -133.78 M, a -100.42% change year over year.
Kronos Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -66.75 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: KRON

Kronos Bio, Inc.

CEO	Dr. Norbert W. Bischofberger Ph.D.
IPO Date	Oct. 9, 2020
Location	United States
Headquarters	1300 South El Camino Real
Employees	58
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Key trends

Past 5 years